Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
2.5.9.3 Orismilast Orismilast (UNI-50001) is an oral B/D selective PDE-4 inhibitor being studied for moderate to severe UC in the UCORIS trial, a Phase 2a open-label single-arm exploratory study that enrolled adults with UC diagnosed for at least 3 months, MES of 2, on stable 5-ASA or immunomodulator therapy for 3 months, with treatment given twice daily for 12 weeks extendable to 52 weeks (81, 82)
How can you prevent weight regain
R., and Mohamed, N
This systematic review published in The Indonesian Journal of General Medicine examined the role of glutathione as an adjunct intervention for fatty liver disease
For injectable applications, a 1993 study using implanted wound chambers compared GHK-Cu treatment against saline controls
Our research and experience in the mens sexual health space is particularly expansive
US$ 28.27
US$ 28.12
US$ 27.75
US$ 28.43
